Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag EstimatesZacks Investment Research • 03/19/26
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 03/19/26
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud ViolationsNewsfile Corp • 03/10/26
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)Zacks Investment Research • 03/09/26
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)Zacks Investment Research • 03/06/26
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell ItselfInvestors Business Daily • 03/03/26
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic reviewProactive Investors • 03/03/26
Theravance plans strategic review, including possible sale, after drug trial failureReuters • 03/03/26
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ActionsPRNewsWire • 03/03/26
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?Zacks Investment Research • 01/28/26
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/23/26
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-TermZacks Investment Research • 01/15/26
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to TradeZacks Investment Research • 12/22/25
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy TranscriptSeeking Alpha • 12/08/25
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/08/25
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?Zacks Investment Research • 12/05/25
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025PRNewsWire • 11/20/25
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?Zacks Investment Research • 11/19/25